Targeting EZHIP and PRC2 interaction in a pediatric brain cancer
Official title: Targeting the Molecular Crosstalk Between EZHIP and PRC2 in PFA Ependymoma
Funded at Ut Southwestern Medical Center · NIH-11343020 · Data updated 2026-11-12
A cancer research grant trying to understand how a protein called EZHIP disrupts a key epigenetic regulator in a rare pediatric brain tumor to guide better treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | June 16, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $384,065 |
| NIH project number | 1R01NS148235-01 |
| Project ID | NIH-11343020 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with PFA (posterior fossa) ependymoma or related pediatric brain tumors may benefit from insights that emerge.
✕Less likely to help
Patients without this specific tumor type may not directly benefit from these findings.
What this research studies
This project looks at how EZHIP, a protein abnormally present in PFA ependymoma, interferes with the PRC2 complex that normally keeps certain genes turned off. Scientists will study how EZHIP both inhibits the enzyme activity of PRC2 and slows it down on specific DNA regions, leading to widespread epigenetic changes. The work will map interactions between EZHIP and PRC2 components to identify targets for therapies aimed at restoring proper gene repression. By focusing on the two PRC2 variants and their accessory subunits, the team hopes to reveal mechanisms that drive this aggressive pediatric brain tumor. Results could point to new strategies to normalize epigenetic regulation in affected children.
Why it matters
Potential benefit: If successful, the project could reveal new therapeutic targets to restore proper gene regulation in PFA ependymoma, potentially slowing tumor growth or improving outcomes.
How similar studies have gone: Prior research shows that targeting PRC2 and epigenetic regulators can slow tumor growth in some brain cancers, but disease-specific strategies for PFA ependymoma are still emerging.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Liu, Xin — Ut Southwestern Medical Center
- Study coordinator: Liu, Xin
Related research
Other NIH-funded projects on the same topics.
-
Condensates and ZFTA-driven Ependymoma in kids
A pediatric brain tumor grant explores how ZFTA fusion proteins drive cancer by forming condensates, with the aim of finding new ways to target these tumors.
-
ZFTA-RELA Ependymoma: uncovering what drives this pediatric brain cancer
A study at St. Jude aims to understand how the ZFTA-RELA gene fusion pushes pediatric brain tumors to grow, with the goal of finding points to intervene and slow or stop cancer progression.
-
PEP-CMV vaccine with nivolumab for pediatric and adult high-grade brain tumors
A phase 1/2 trial tests a CMV-targeted vaccine plus a PD-1 blocker for newly diagnosed and recurrent high-grade brain tumors in children and adults.
-
Understanding ZFTA-RELA Brain Cancer in Children
This project aims to understand how a specific genetic change drives an aggressive type of children's brain cancer called ependymoma, hoping to find new ways to treat it.
-
Investigating how EZHIP interacts with PRC2 in a specific brain tumor in young children
This study is looking at how a protein called EZHIP interacts with a group of proteins that help control the growth of a specific type of brain tumor in young children, with the hope of finding new ways to treat this challenging condition.
-
Investigating the role of a protein in a specific type of brain tumor.
This study is looking at a tough type of brain tumor called ependymomas, especially in patients with a specific gene change, to see how a protein called FACT interacts with it, with the goal of finding new ways to treat these tumors better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.